This study is currently not recruiting participants.

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis

Investigating the Safety and Effects of an Investigational Medication for Relapsing-Remitting MS

Not Recruiting
18 years - 65 years
All
Phase N/A

Brief description of study.

The purpose of this research study is to test the long-term safety and treatment effect of ALKS 8700 in subjects who have relapsing-remitting MS.

Detailed description of study

The purpose of this study is to test the long-term safety, tolerability and treatment effect of ALKS 8700 administered up to 96 weeks for subjects who have relapsing-remitting MS.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: multiple sclerosis
  • Age: 18 years - 65 years
  • Gender: All

The purpose of this study is to test the long-term safety and treatment effects of an investigational medication in people with relapsing-remitting multiple sclerosis (MS). Relapsing-remitting MS is a type of MS where people experience periods of new or worsening symptoms followed by recovery periods.

Participants will receive the investigational medication for up to 96 weeks. The study will monitor how well participants tolerate the medication and any effects it may have on their condition.

  • Who can participate: Participants must be adults diagnosed with relapsing-remitting MS. Key eligibility factors include specific health criteria related to MS and overall health status.
  • Study details: Participants will take the investigational medication and their health will be monitored to assess safety and effects.
  • Study Timelines: The study will last 96 weeks.
Updated on 19 Feb 2024. Study ID: 1512139135

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team